Company profile: Acumen Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of targeted therapies in development for Alzheimer's disease and related neurodegenerative diseases, including ACU193, a monoclonal antibody targeting toxic soluble amyloid-beta oligomers (AβOs) for early Alzheimer's, and the INTERCEPT-AD Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with mild cognitive impairment or mild dementia due to Alzheimer's.
Products and services
- INTERCEPT-AD Trial: A Phase 1 study evaluating ACU193’s safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease
- ACU193: A clinical-stage monoclonal antibody that targets toxic soluble amyloid-beta oligomers (AβOs) for the treatment of early Alzheimer’s disease
- Targeted Therapies Development: A research-driven program developing targeted therapies for the safe and effective treatment of Alzheimer’s Disease and related neurodegenerative diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acumen Pharmaceuticals
iPierian
HQ: United States
Website
- Description: Provider of a drug discovery platform leveraging induced pluripotent stem cells to discover and develop therapies for neurodegenerative diseases, including SMA, ALS, and Parkinson's, addressing other major unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iPierian company profile →
Envoy Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery focused on novel drugs for neurological and psychiatric diseases, using bacTRAP technology to identify proteins in vivo produced by specific cell types without isolating those cells, aiming for superior efficacy and fewer side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Envoy Therapeutics company profile →
Neuraxpharm
HQ: Germany
Website
- Description: Provider of branded and generic CNS pharmaceuticals and nutraceuticals in main European countries, developing and commercializing products for CNS disorder prevention and treatment. Develops and manufactures finished dosage forms (mainly solid oral) for CNS and other areas; includes Buccolam for acute pediatric seizures and Preventan for immune support. Also offers LepsiApp for epilepsy management, R&D (actives, bioequivalence, regulatory), and pharmacovigilance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuraxpharm company profile →
Impulse Monitoring
HQ: United States
Website
- Description: Provider of intraoperative neurophysiologic monitoring solutions to hospitals and other healthcare facilities, offering insight into the nervous system during spinal, nerve, and brain-related surgeries. Solutions include IONM delivering real-time data and alerts to help reduce surgical risk, plus EEG, ECoG, EMG, and SSEP for diagnosis and intraoperative monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Impulse Monitoring company profile →
Cenes
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical products, developing and commercializing drugs for pain control, sedation, and other central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cenes company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acumen Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acumen Pharmaceuticals
2.2 - Growth funds investing in similar companies to Acumen Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acumen Pharmaceuticals
4.2 - Public trading comparable groups for Acumen Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →